Maxim Group analyst Jason McCarthy maintained a Hold rating on Cellular Biomedicine Group (NASDAQ: CBMG) today. The company’s shares opened today at $17.80.
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 9.5% and a 44.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
Cellular Biomedicine Group has an analyst consensus of Moderate Buy, with a price target consensus of $32.
See today’s analyst top recommended stocks >>
Based on Cellular Biomedicine Group’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $8.5 million. In comparison, last year the company had a GAAP net loss of $6.16 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellular Biomedicine Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies.
